{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:52:51Z","timestamp":1790614371480,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lanmic.2024.101028","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:19:19Z","timestamp":1746076759000},"page":"101028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-6855","authenticated-orcid":false,"given":"Audrey","family":"Godin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-2288","authenticated-orcid":false,"given":"Elizabeth B","family":"Brickley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth I","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy F","family":"Wieland-Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-0628","authenticated-orcid":false,"given":"Joshua A","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Modlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minetaro","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda S","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4216-679X","authenticated-orcid":false,"given":"Chris","family":"Gast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"S\u00e1ez-Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo W","family":"R\u00fcttimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"De Coster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2024.101028_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.lanmic.2024.101028_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.lanmic.2024.101028_bib3","series-title":"Polio Eradication Strategy, 2022\u20132026: Delivering on a promise","year":"2021"},{"key":"10.1016\/j.lanmic.2024.101028_bib4","series-title":"Standard operating procedures: responding to a poliovirus event or outbreak","year":"2022"},{"key":"10.1016\/j.lanmic.2024.101028_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/pathogens13040273","article-title":"Novel oral polio vaccine type 2 use for polio outbreak response: a global effort for a global health emergency","volume":"13","author":"Kurji","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.lanmic.2024.101028_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials","volume":"397","author":"De Coster","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2024.101028_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"S\u00e1ez-Llorens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2024.101028_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(22)02397-2","article-title":"Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial","volume":"401","author":"Zaman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2024.101028_bib9","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2666-5247(22)00254-3","article-title":"Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials","volume":"3","author":"Wahid","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2024.101028_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-022-00437-5","article-title":"Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children","volume":"7","author":"Wahid","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.lanmic.2024.101028_bib13","series-title":"Poliovirus: methods and protocols","first-page":"145","article-title":"Standardized methods for detection of poliovirus antibodies","author":"Weldon","year":"2016"},{"key":"10.1016\/j.lanmic.2024.101028_bib14","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/CVI.05225-11","article-title":"Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum","volume":"18","author":"Arita","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"suppl 1","key":"10.1016\/j.lanmic.2024.101028_bib15","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1093\/cid\/ciy603","volume":"67","author":"Brickley","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib16","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/infdis\/jit671","article-title":"Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination","volume":"209","author":"Wright","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2019-001613","article-title":"Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden","volume":"4","author":"Brickley","year":"2019","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.lanmic.2024.101028_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/infdis\/jiaa783","article-title":"Intestinal antibody responses to 2 novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium","volume":"226","author":"Brickley","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/jiab507","article-title":"Fecal shedding of 2 novel live attenuated oral poliovirus type 2 vaccine candidates by healthy infants administered bivalent oral poliovirus vaccine\/inactivated poliovirus vaccine: 2 randomized clinical trials","volume":"226","author":"Gast","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(23)00688-6","article-title":"Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study","volume":"24","author":"Cooper","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib21","doi-asserted-by":"crossref","first-page":"e1807","DOI":"10.1016\/S2214-109X(22)00412-0","article-title":"Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021","volume":"10","author":"Mirzoev","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2024.101028_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1473-3099(23)00631-X","article-title":"Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study","volume":"24","author":"Bashorun","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib23","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1016\/S2214-109X(23)00116-X","article-title":"Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey","volume":"11","author":"Kennedy","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2024.101028_bib24","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(23)00139-1","article-title":"Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial","volume":"23","author":"Wilkinson","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/infdis\/jix556","article-title":"Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent opv and either high-dose or standard inactivated polio vaccine","volume":"217","author":"Brickley","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/jiaa390","article-title":"A randomized phase 4 study of immunogenicity and safety after monovalent oral type 2 sabin poliovirus vaccine challenge in children vaccinated with inactivated poliovirus vaccine in Lithuania","volume":"223","author":"Bandyopadhyay","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.lanmic.2024.101028_bib28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","article-title":"Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants","volume":"16","author":"Wright","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.lanmic.2024.101028_bib29","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/ciy604","article-title":"Does simultaneous administration of bivalent (types 1 and 3) oral poliovirus vaccine and inactivated poliovirus vaccine induce mucosal cross-immunity to poliovirus type 2?","volume":"67","author":"Resik","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101028_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/163.1.1","article-title":"Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines","volume":"163","author":"Onorato","year":"1991","journal-title":"J Infect Dis"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524724002969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524724002969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T22:34:10Z","timestamp":1748990050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524724002969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666524724002969"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2024.101028","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2024.101028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101104","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101028"}}